Augmentation of Manufacturing Capacity for COVAXIN production under Mission COVID Suraksha

Apr 17, 2021 | Business

Under Atmanirbhar Bharat 3.0 Mission COVID Suraksha was announced by the Government of India, to accelerate the development and production of Indigenous COVID Vaccines. This is being implemented by Department of Biotechnology Govt of India.

Under the Mission the Department of Biotechnology Govt of India is providing financial support as Grant to vaccine manufacturing facilities for enhanced production capacities. The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July – August 2021 i.e increasing the production from 1 crore vaccine doses in April, 2021 to 6-7 crore vaccine dose/month in July – August. It is expected to reach nearly 10 crore doses per month by Sep 2021.

Few weeks back, Inter-ministerial teams had visited the sites of 2 main vaccine manufacturers in India to get their inputs on how production can be ramped up. In this period, there have been extensive reviews and feasibility studies on the plans being discussed with vaccine manufacturers.

As a part this augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufactures are being upgraded with required infrastructure and technology. Financial support is being provided as grant from GoI to the tune of appx Rs 65 Cr to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production.

3 public sectors companies are also being supported to increase the capacity of vaccine production.

  • Haffkine Biopharmaceutical Corporation Ltd , Mumbai –a State PSE under State Govt of Maharashtra. Financial support as grant from GoI to the tune of appx Rs 65 Cr will be provided for this facility to be made ready for manufacturing.The Haffkine Biopharmaceuticals Ltd had asked for around 12 months to complete this task.However, the Central government has asked them to expedite and complete the task urgently within 6 months. The facility will have a capacity of 20 million dozes per month, once functional.
  • Indian Immunologicals Limited (IIL), Hyderabad –A facility under National Dairy Development Board and Bharat Immunologicals and Biologicals Limited (BIBCOL) , Bulandshahr  a CPSE under Department of Biotechnology ,Govt of India will also be supported to prepare there facility to provide 10-15 million dozes per month by Aug – Sep 2021.

****

DS/AK

(Release ID: 1712271)
Visitor Counter : 174




A.P. Honda, Thai Honda Manufacturing and HPD have merged to form a new company named “Thai Honda Manufacturing” combining their sales and production capabilities

Apr 2, 2021 | Business

Honda announced an amalgamation of A.P. Honda Co., Ltd., Thai Honda Manufacturing Co., Ltd., and HPD Co., Ltd., a shareholding company, — forming a new company named “Thai Honda Manufacturing Co., Ltd.” The establishment of the new company was effective on the 31st of March 2021.

“This amalgamation will strengthen Honda motorcycle operations in Thailand, making the brand more responsive to customers and ready for future market needs” said Mr. Masayuki Igarashi, Chief Officer for Regional Operations (Asia & Oceania), Honda Motor Co., Ltd.

The new company will combine the strengths of each company with a focus on delivering new motorcycles and power products that exceed customer expectations. This amalgamation will also eliminate redundancies, and increase speed and accuracy.

Mr. Shigeto Kimura, former president of A.P. Honda Co., Ltd. will be in charge as the first president of the new company to ensure a smooth consolidation of sales and production sides.
There will be no change in the distribution channel of Honda motorcycles and power products in Thailand for the time being. Honda Wing Center network will still distribute Honda motorcycles while Honda BigWing network will serve customers with its big bikes (400cc or above). CUB House, the showroom for value-added products, will still run its business without any change.


Topic: Press release summary